Developing a biomarker – either for diagnosis or supporting drug development – is a costly and time-consuming process. Over the years, we’ve built up reliable experience concerning this topic. That’s why in this blog, we’ll share three rules to remember when developing biomarkers: one during ...
Discovering a strong biomarker is an expensive and time-consuming process. One of the key takeaways is to take your time and look at the data before you start testing for biomarkers. Why? Because junk in equals junk out. You can run the best models and the most advanced statistical analysis. But ...
About the client Cytura Therapeutics is an early-stage pharmaceutical company based in the Netherlands that develops novel drugs targeting genomic instability in cancer. For their project with BioLizard, Cytura wanted to know whether treatment of human B cells with various drug combinations induced ...
Mdxhealth is a front runner in epigenetic research with a proven track record of identifying, developing, validating and delivering molecular diagnostic assays. They provide functional genomic data that can be used for personalised cancer risk assessment, with specific focus on prostate cancer.
